Biocon Biologics, Author at Biocon Biologics

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics U.S. Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics EU Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>

Leaving the Biocon Biologics site

You are now leaving the Biocon Biologics page for a Biocon Biologics affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Brazil

Egypt

Europe

Hong Kong

Malaysia

Mexico

Morocco

Philippines

Saudi Arabia

South Africa

Taiwan

Thailand

Tunisia

Turkey

UAE

USA

Vietnam

Global HQ

Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%

Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru

Biocon Biologics issues a statement in response to the media reports related to bribery allegations

Biocon Biologics Denies Bribery Allegations

University of Glasgow officially Opens Mazumdar-Shaw Advance Research Centre

Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada

Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9%

Biocon Biologics’ Insugen® Awarded a Three-Year Contract by Ministry of Health, Malaysia

Biocon Biologics’ Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion

University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw

Agree >>

Agree >>

Agree >>